Qing Peng1, Carrie A Karvonen-Gutierrez1, John F Randolph2, Bin Nan3, Daniel McConnell1, Siobán D Harlow1. 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan. 2. 2Division of Reproductive Endocrinology and Infertility, University of Michigan Health System, Ann Arbor, Michigan. 3. 3Department of Statistics, University of California at Irvine, Irvine, California.
Abstract
CONTEXT: Women with polycystic ovary syndrome (PCOS) have a higher prevalence of metabolic syndrome (MetS), but whether they develop MetS earlier than women without PCOS is unknown. Understanding the impact of PCOS on the timing of MetS onset is important for screening and clinical care in this population. DESIGN: Women with PCOS-like status (PCOSp) were identified from participants of the Michigan Bone Health and Metabolism Study based upon history of irregular menstrual cycles, high free-androgen index, and high levels of antimüllerian hormone. MetS was defined according to the Adult Treatment Panel III criteria. Age at MetS onset was compared between women with and without PCOSp using an accelerated failure time model adjusted for baseline education, lifestyle factors, and midlife body weight. RESULTS: Among the 496 women in the analysis, 11.7% (n = 58) were determined to have PCOSp. Over a mean follow-up of 11 years, 20 women with PCOSp and 136 women without PCOSp developed MetS. After adjusting for smoking, education, and physical activity, women with PCOSp developed MetS at an age 14.4% (95% CI -22.7, -5.2) younger than women without PCOSp. The magnitude of the association was attenuated to 5.4% in models additionally adjusted for body mass index (95% CI -12.4, 2.1). Because a typical study participant without PCOSp developed MetS at 51.5 years old, 5.4% translates to almost 3 years earlier onset of MetS for a comparable woman with PCOSp. CONCLUSIONS: Women with PCOSp develop MetS at a younger age. Earlier screening for MetS in women with PCOS may be warranted.
CONTEXT: Women with polycystic ovary syndrome (PCOS) have a higher prevalence of metabolic syndrome (MetS), but whether they develop MetS earlier than women without PCOS is unknown. Understanding the impact of PCOS on the timing of MetS onset is important for screening and clinical care in this population. DESIGN:Women with PCOS-like status (PCOSp) were identified from participants of the Michigan Bone Health and Metabolism Study based upon history of irregular menstrual cycles, high free-androgen index, and high levels of antimüllerian hormone. MetS was defined according to the Adult Treatment Panel III criteria. Age at MetS onset was compared between women with and without PCOSp using an accelerated failure time model adjusted for baseline education, lifestyle factors, and midlife body weight. RESULTS: Among the 496 women in the analysis, 11.7% (n = 58) were determined to have PCOSp. Over a mean follow-up of 11 years, 20 women with PCOSp and 136 women without PCOSp developed MetS. After adjusting for smoking, education, and physical activity, women with PCOSp developed MetS at an age 14.4% (95% CI -22.7, -5.2) younger than women without PCOSp. The magnitude of the association was attenuated to 5.4% in models additionally adjusted for body mass index (95% CI -12.4, 2.1). Because a typical study participant without PCOSp developed MetS at 51.5 years old, 5.4% translates to almost 3 years earlier onset of MetS for a comparable woman with PCOSp. CONCLUSIONS:Women with PCOSp develop MetS at a younger age. Earlier screening for MetS in women with PCOS may be warranted.
Authors: Nadine M P Daan; Yvonne V Louwers; Maria P H Koster; Marinus J C Eijkemans; Yolanda B de Rijke; Eef W G Lentjes; Bart C J M Fauser; Joop S E Laven Journal: Fertil Steril Date: 2014-09-16 Impact factor: 7.329
Authors: MaryFran R Sowers; Aimee D Eyvazzadeh; Daniel McConnell; Matheos Yosef; Mary L Jannausch; Daowen Zhang; Sioban Harlow; John F Randolph Journal: J Clin Endocrinol Metab Date: 2008-07-01 Impact factor: 5.958
Authors: Michelle L Meyer; Daniela Sotres-Alvarez; Anne Z Steiner; Larry Cousins; Gregory A Talavera; Jianwen Cai; Martha L Daviglus; Laura R Loehr Journal: J Clin Endocrinol Metab Date: 2020-03-01 Impact factor: 5.958